The neurobiological correlates of anhedonic depression in Parkinson’s disease; associations between dopamine function and functional pathways

RadboudUMC Nijmegen, Department of Psychiatry0 个研究点目标入组 75 人开始时间: 待定最近更新: 2024年2月28日

适应症

试验速览

暂无简介。

•A diagnosis of PD with <=5 years duration, defined as time since diagnosis made by a neurologist.
•Subject can read and understand Dutch.
•Subject is willing, competent, and able to comply with all aspects of the protocol
•BDI score ?14 ánd meeting DSM-criteria for a depression including the criterium of a sad mood (depressed PD group)
•BDI score <8 ánd in the 5 past years and/or currently not meeting DSM-criteria for a depression (non-depressed PD control group)

•Contraindications for MRI, e.g., claustrophobia, presence of an active implant, pacemaker, insulin pump, neurostimulator, ossicle prosthesis, pregnancy, and/or other medical device or other non-removable metal part incompatible with MRI.
•Contraindications for PET e.g., inability to lie flat or lie still for the duration of the scan, claustrophobia (occasionally).
•Use of medication or drugs with evident DAT-binding like methylphenidate, buproprion, amphetamines, cocaine that cannot be discontinued according to the PET-protocol. Note that we allow use of anti-depressants with the exception of those antidepressants with a high DAT binding defined as a relatively low Ki of <1000 (, i.e. for the Netherlands buproprion, duloxetine and sertraline). Moreover, we will exclude patients using antidepressants at higher than minimal effective dosages used for antidepressive effects when the Ki is <10000 (i.e. for the Netherlands amitryptiline, clomipramine, maprotiline, nortriptyline, fluoxetine, paroxetine).
•Being diagnosed with dementia (defined as a Montreal Cognitive Assessment (MoCA) <21/30 (Dalymple-Alford 2010), assessed ON Parkinson medication).
•Psychiatric diagnosis of bipolar disorder.
•Presence of current psychotic symptoms.

发起方

RadboudUMC Nijmegen, Department of Psychiatry